CF
INBX icon

Corebridge Financial’s Inhibrx INBX Stock Holding History

Corebridge Financial’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-5,681
Closed -$79.5K – 1324
2025
Q1 		$79.5K Sell
5,681
-84
-1% -$1.14K ﹤0.01% 2555
2024
Q4 		$88.8K Sell
5,765
-436
-7% -$6.64K ﹤0.01% 2603
2024
Q3 		$97.1K Buy
6,201
+569
+10% +$8K ﹤0.01% 2626
2024
Q2 		$79.8K Buy
+5,632
New +$88K ﹤0.01% 2714

Other funds holding INBX

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Corebridge Financial's INBX Position: Q2 2025 in Review

Corebridge Financial sold out of Inhibrx (INBX) in Q2 2025, closing a stake of 5,681 shares — an estimated $79.5K sold.

Corebridge Financial first reported a position in INBX in Q2 2024 and held it in 4 quarters. The position peaked at $97.1K in Q3 2024. 88 funds tracked by Wall St. Rank hold INBX as of Q2 2025.

  • Corebridge Financial reported no remaining Inhibrx position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 5,681 Inhibrx shares in Q2 2025, an estimated $79.5K.
  • Corebridge Financial first reported a position in Inhibrx in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Inhibrx position peaked at $97.1K in Q3 2024.
  • 88 funds tracked by Wall St. Rank held Inhibrx as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.